BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Preventing cancer with vaccines: progress in the global control of
  cancer - Dr Mark Kane
DTSTART:20121024T163000Z
DTEND:20121024T180000Z
UID:TALK38608@talks.cam.ac.uk
CONTACT:7887
DESCRIPTION:The cancer control community is largely unaware of great advan
 ces in the control of major human cancers with vaccines\, including the dr
 amatic control of hepatocellular (liver) cancer with hepatitis B virus (HB
 V) vaccine\, now used routinely in more than 90% of countries. The biotech
 nology revolution has given us a new generation of highly effective vaccin
 es against major global killers\, global funding for immunization is order
 s of magnitude higher than ever before\, and the vaccine delivery infrastr
 ucture has improved very significantly even in the poorest countries. Live
 r cancer is the greatest cause of cancer deaths in men of sub-Saharan Afri
 ca and much of Asia. Even in highly endemic countries such as China\, the 
 prevalence of HB surface antigen carriers has fallen from 10% to 1%-2% in 
 immunized cohorts of children\, and liver cancer has already fallen dramat
 ically in Taiwanese children. The Global Alliance for Vaccines and Immuniz
 ation (now called the GAVI Alliance) has greatly expedited this success by
  providing HBV vaccine free for five years in most of the world's 72 poore
 st countries. HBV vaccination can serve as a model for the global control 
 of human papillomavirus (HPV)-related cervical and other cancers with HPV 
 vaccines. Cervical cancer is the greatest cause of cancer death in women i
 n many developing countries\; HPV vaccines are highly effective in prevent
 ing HPV infection and precancerous lesions in women\, and the quadrivalent
  vaccine also prevents genital warts in men and women and precancerous ana
 l lesions in men. HPV is causing a growing proportion of oropharyngeal can
 cers\, and HPV-related noncervical cancers (penile\, anal\, and oropharyng
 eal) may exceed the incidence of cervical cancer within a decade in indust
 rial countries\, where cervical screening is effective\, causing reevaluat
 ion of male HPV immunization. In developing countries\, few women are scre
 ened for cervical precancerous lesions\, making immunization even more imp
 ortant. Currently\, 26 primarily industrial countries routinely immunize g
 irls with HPV vaccine\, and GAVI will begin to accept applications in 2012
  to fund vaccine in developing countries that can deliver the vaccine and 
 if GAVI can negotiate an acceptable price (one manufacturer has already of
 fered a price of $5 per dose).
LOCATION:Yusuf Hamied Theatre\, Christ's College
END:VEVENT
END:VCALENDAR